The proposed case covers purchases from January 14, 2025 to May 6, 2026 and follows Zoetis’s 21.5% share drop after a guidance cut and alleged undisclosed product-adoption and market-share pressures.
Zoetis Inc. investors who bought securities between January 14, 2025 and May 6, 2026 have until July 27, 2026 to seek appointment as lead plaintiff in a securities class action pending in the United States District Court for the Southern District of New York. The suit, captioned City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., No. 26-cv-04401 (S.D.N.Y.), alleges materially false or misleading statements and omissions about weakening adoption of Librela after FDA safety warnings, market-share losses for Simparica Trio to a lower-priced competitor, and competitive pressure on Apoquel and Cytopoint. The case highlights Zoetis’s May 7, 2026 first-quarter results, when the animal health company reported net income of $601 million, unchanged from a year earlier, lowered full-year 2026 profit guidance to $6.85 to $7.00 a share from $7.00 to $7.10, and said softer veterinary visits and price-sensitive pet owners hurt demand. Zoetis shares fell $23.91, or 21.5%, to close at $87.31 that day.